TABLE 4.

De novo CTL responses detected in convalescent micea

EBOV proteinEpitope sequenceAmino acid positionRestrictionbResponse in mice pretreated with:c
MAbVRP-GPVRP-NP
GPVSTGTGPGAGDFAFHK141-155H-2d+++
WIPYFGPAAEGIYTE531-545H-2b+++
EYLFEVDNL231-239H-2d+++
NPVYQVNNLEEIC44-52H-2b+++
GQFLSFASL148-156H-2b++
SFKAALSSL279-287H-2d+++
DAVLYYHMM663-671H-2b+++
VP24KFINKLDALH159-168H-2d+++
NYNGLLSSI171-179H-2d+++
PGPAKFSLL214-222H-2d+++
VP30KFSKSQLSLLCETHLR181-196H-2dNDNDND
181-196H-2bNDNDND
DLQSLIMFITAFLNI231-245H-2b+NDND
231-245H-2d+NDND
VP35CDIENNPGL45-53H-2b+++
MVAKYDHL138-145H-2b+++
TVPQSVREAFNNL190-202H-2dNDNDND
RNIMYDHL225-323H-2b+++
PGFGTAFHQLVQVICK233-248H-2dNDNDND
VP40LRIGNQAFLQEFVLPP150-165H-2b+++
AFLQEFVLPPVQLPQ160-175H-2dNDNDND
YFTFDLTALK171-180H-2dNDNDND
TESPEKIQAI232-141H-2d+++
  • a Cellular responses were evaluated by ICC or ELISPOT assay in some convalescent mice to determine whether de novo responses were observed in pretreated mice and to provide additional evidence that the CTL responses identified following vaccination are relevant.

  • b The cellular responses were detected in BALB/c (H-2d) or C57BL/6 (H-2b) mice according to the MHC restriction indicated.

  • c Mice were pretreated with MAbs to Ebola virus GP 1 day before challenge (MAb) or vaccinated with VRP expressing Ebola virus GP (VRP-GP) or NP (VRP-NP) twice before challenge with 1,000 PFU of mouse-adapted EBOV. ND, not determined.